Actuate Therapeutics (NASDAQ:ACTU) Now Covered by HC Wainwright

HC Wainwright began coverage on shares of Actuate Therapeutics (NASDAQ:ACTU) in a report released on Monday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $20.00 price objective on the stock.

Actuate Therapeutics Trading Up 2.1 %

Shares of NASDAQ ACTU opened at $7.40 on Monday. Actuate Therapeutics has a 12-month low of $5.51 and a 12-month high of $11.73. The stock has a fifty day moving average price of $8.16 and a 200 day moving average price of $8.07.

Institutional Trading of Actuate Therapeutics

Several large investors have recently added to or reduced their stakes in ACTU. Freestone Capital Holdings LLC acquired a new stake in shares of Actuate Therapeutics during the fourth quarter valued at about $80,000. Envestnet Asset Management Inc. acquired a new position in Actuate Therapeutics in the fourth quarter worth about $83,000. OMERS ADMINISTRATION Corp acquired a new position in Actuate Therapeutics in the fourth quarter worth about $84,000. Sigma Planning Corp acquired a new position in Actuate Therapeutics in the fourth quarter worth about $128,000. Finally, Mercer Global Advisors Inc. ADV acquired a new position in Actuate Therapeutics in the fourth quarter worth about $130,000.

Actuate Therapeutics Company Profile

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.